A collaborative study, including the CSU Mycobacteria Research Laboratories, provides an important new basis for comparing the effectiveness of different tuberculosis treatments and accelerating the development of shorter regimens.
An interdisciplinary CSU team is advancing a COVID-19 vaccine candidate with additional NIH support, that relies on riboflavin and UV light technology to create inactivated virus.
Associate professors Marcela Henao Tamayo and Brendan Podell will led an interdisciplinary team from the CSU Mycobacteria Research Laboratories to progress a vaccine for tuberculosis.
Name the 2017 Zoetis Research Excellence Award recipient, Dr. Brendan Podell reflects on his academic and research path that led to his ongoing investigation of tuberculosis and diabetes.
Continuing their discoveries on the relationship between tuberculosis and metabolism, the CSU team will test new strategies for treatment of tuberculosis.